Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab-IRDye800CW fluorescence-guided surgery in sinonasal inverted papilloma
NL-OMON45848Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- May 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of bevacizumab-IRDye800CW in sinonasal inverted papilloma, sponsored by University Medical Center Groningen. Primary endpoints: Macroscopic fluorescent signal levels and tracer distribution, Real-time fluorescence quantification by spectroscopy and 2 more. Started May 2019; status: active, not recruiting.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
sinonasal inverted papilloma
Beyond the preview
Go deeper on NL-OMON45848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45848.